News Release

One in 6 lupus patients readmitted to hospital within 30 days of discharge

Readmissions more likely in black and Hispanic systemic lupus erythematosus patients

Peer-Reviewed Publication

Wiley

Jinoos Yazdany, University of California San Francisco

image: This is. Dr. Jinoos Yazdany. view more 

Credit: Dr. Yazdany

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged. Results published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), show that black and Hispanic SLE patients were more likely to be readmitted than white patients. Readmissions among patients insured by Medicare or Medicaid were also more likely compared to patients covered by private insurance.

Lupus is a systemic, autoimmune disease where an overactive immune system attacks healthy joints and organs. Medical evidence reports that up to 25% of SLE patients require treatment in the hospital each year, accounting for more than 140,000 hospitalizations in the U.S. Moreover, SLE has the sixth highest rate of readmission among all medical conditions in the U.S. according to a 2010 study by Elixhauser et al.

"SLE patients have one of the highest hospital readmission rates compared to those with other chronic illnesses," explains Jinoos Yazdany, M.D., M.P.H. from the Division of Rheumatology at the University of California, San Francisco. "Our study is the first large-scale examination of early readmissions following hospitalization due to SLE."

Researchers examined 55,936 hospitalizations using hospital discharge databases that included roughly 85% (810) of U.S. hospitals. The team analyzed data of 31,903 lupus patients readmitted between 2008 and 2009 from 5 states – California, Florida, New York, Utah and Washington. Analyses included SLE patients 18 years of age or older who were readmitted to the hospital and excluded hospital transfers, discharges to nursing or rehabilitation facilities, maternity-related admissions or patients who died.

Results show that there were 9,244 (17%) readmissions into the hospital within 30 days of discharge. The readmissions were found among 4,916 individual SLE patients. Clinical features most associated with readmission included patients with lupus nephritis (kidney inflammation), serositis (inflammation of the lining of the lungs, heart, abdomen, or abdominal organs) and thrombocytopenia (low blood platelet count). Age was inversely related to readmission, suggesting that severe organ involvement in younger SLE patients may be partly to blame.

Further analyses show risk-adjusted readmission rates to be lower in New York and higher in Florida, compared to California. Hospitals with higher readmissions for SLE did not have higher admissions for other chronic conditions such as heart failure or pneumonia, which the authors believe is condition-specific to SLE readmissions and warrants further study. Dr. Yazdany concludes, "The significant geographic and hospital-level variation in readmission rates signals a need for quality improvement efforts in lupus."

###

This study was funded in part by the National Institute of Arthritis and Musculoskeletal and Skin diseases (award numbers K23 AR060259 and P60 AR053308).

This study is published in Arthritis & Rheumatology. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com.

Full citation: "Thirty-day Hospital Readmissions in Systemic Lupus Erythematosus: Predictors and Hospital and State-level Variation." Jinoos Yazdany, Ben J. Marafino, Mitzi L. Dean, Naomi S. Bardach, Reena Duseja, Michael M. Ward and R. Adams Dudley. Arthritis & Rheumatology; Published Online: August 11, 2014 (DOI: 10.1002/art.38768).

URL Upon Publication: http://doi.wiley.com/10.1002/art.38768

Author Contact: To arrange an interview with Dr. Yazdany, please contact Peter Farley with UCSF at Peter.Farley@ucsf.edu.

About the Journal

Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.

About Wiley

Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.

Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.wiley.com.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.